2002- Consumer Research Council of America “Guide to America’s Best Physicians.”
2002-6 Appointed to National Cardiac Panel for Vicor Technologies
2004 Nominated by peers to, “Best Doctors in America.”
2006-9 Boston Magazine Web Site, “Best Doctors”
2006&7 Consumer Research Council of America “Guide to America’s Best Physicians.”
2007 Full time faculty award for Excellence in Teaching as voted by the Department of Medicine House Staff, Boston University.
2008 Strathmore’s “Who’s Who” Honors.
2008 Strathmore’s “Who’s Who “Professional of the Year in Pulmonary/Critical Care Medicine”
2008 Whitney’s “Who’s Who” Honors.
2008 Crystal APPLE award, American Association of Colleges of Pharmacy
Clinical and Basic Science Awards
1985 Sub-investigator for "A double-blind randomized comparative study
of the efficacy of oral cromolyn sodium in the prevention of
allergic mediated asthma."
1991-2 Principle Investigator for “A randomized double-blind multicenter of the comparison of intravenous/oral temafloxacin versus i.v./oral cefuroxime with or without erythromycin in community acquired pneumonia.” Abbot Laboratories..
1984-5 National Research Service Award "Histamine Induced Human Lymphokines" Institutional Post-doctoral Fellowship #1 F32 HL 06975-01 CLN-1.
1985-6 National Research Service Award "Human T-T Hybridoma-derived Lymphocyte Chemoattractants" Institutional Post-doctoral Fellowship #2 F32 HL 06975-02 CLN-1.
1986-7 RAG "Biochemical Definition of a Lymphocyte Chemoattractant Lymphokine."
1987-91 Merit Review "Biochemical Definition of a Lymphocyte Chemoattractant Lymphokine."
1991-6 SCOR "Inflammatory Cell Function in Normal and Diseased Lung." NIH p50HL46563-03.
1999-05 RO1 “Oral Cyclophosphamide vs. Oral Placebo in SSC Alveolitis.” NIH NHLBI 1U01HL60682-01A1
1995-7 Co-PI for “The molecular biology of lung cancer.” Genzyme
1999-02 NO1 “Clinical Centers for Feasibility Studies of Retinoid Treatment in Emphysema.”
NIH NHLBI, NO1 HR 96141
2001-5 Co-PI for “ A multicenter randomized controlled trial comparing the safety and efficacy of surfaxinR (Lucinacant) delivered via bronchoscopic segmental lavage to standard of care in patients with acute respiratory distress syndrome (ARDS). Protocol No: JL4-ARDS-04. Discovery Laboratories.
2002-5 Co-PI BUILD2 clinical trial; “Bosentan Use in Interstitial Lung Disease associated
“Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung
Disease” NIH NHLBI HL089758-01A1
Active non-funded IRB approved Protocols 2009-10 Randomized, placebo controlled trial of the effectiveness of statins for preventing mortality following ICU admission for influenza complications.
2010-11 Utilization of banked bronchoalveolar lavage cells, fluid and serum obtained from subjects with scleroderma who have undergone evaluation and/or treatment for active interstitial lung disease.
American Thoracic Society
American Association for the Advancement of Science
Society for Critical Care Medicine
1998-02 Elected and served on Bedford, MA Board of Health
Symposia from the Scleroderma Lung Study 2003 ATS; NHLBI Clinical Trial of Cyclophosphamide in Slceroderma Lung Disease (Scleroderma Lung Study). Strange, C, Tashkin DP, Clements P, Goldin J and the SLS investigators.
2004 RSNA ; Chest HRCT in Scleroderma Lung Disease: The Ground Glass Dilemma
2005 ATS; The Scleroderma Lung Study: Lessons for Interstitial Lung Disease.
2005 ACR; Plenary Session: The Scleroderma Lung Study (SLS) Shows The Beneficial Effects Of Cyclophsophamide (CYC) Over Placebo (PL) In Systemic Sclerosis (SSc) Patients With Active Alveolitis.
1. Medscape, “An Expert Interview with Art Theodore,MD.” http://www.medscape.com/viewarticle/ 490266.
3. Clearment, G and AC Theodore. Arterial Catheterization. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, 2007, rev 2008, rev 2009, rev 2010.
4. Theodore, AC and LS Jefferson. Oxygenation and mechanisms of hypoxemia. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, 2007, rev 2008, rev 2009, rev 2010.
5. Theodore, AC. Understanding Scleroderma: Uncovering the layers of a chronic disease. On HealthRadio.net (http://www.patientpower.info/). 2007.
6. Theodore, AC. Understanding Scleroderma: Emerging Treatments for Scleroderma. On HealthRadio.net (http://www.patientpower.info/). 2008.
1. Theodore AC, Beer DJ, Picarella DE, Rosenwasser LJ, Center DM: Production of lymphotactic lymphokines by human T-T cell hybridomas. Fed Proc 43(6):1603, 1984.
2. Hollingsworth HM, Kornfeld H, Theodore AC, Center DM, Rosenwasser LJ, and Beer DJ: Functional studies in atopic subjects provide evidence for further subfractionation of the histamine type-2 receptor-bearing human lymphocyte population. Am Rev Respir Dis 129(4):A48, 1984.
3. Theodore AC, Beer DJ, Kornfeld H, Berman JS, Cruikshank WW, and Center DM: CEM T lymphoblastoid line as a model for IL2-induced human T cell migration. Fed Proc 44:1292, 1985.
4. Berman JS, Cruikshank WW, Theodore AC, and Center DM: The chemokinetic activity of a T4+ subset-specific chemoattractant is blocked by FAB fragments of antibody to the T4 anigen. Fed Proc 45(3):273, 1986.
5. Cruikshank WW, Berman JS, Theodore AC, and Center DM: Lymphocyte chemoat- tractant factor (LCF) enhances the expression of the HLA-Dr antigen onhuman monocytes and T4+ lymphocytes. Fed Proc 45(3):273, 1986.
6. Cruikshank WW, Theodore AC, Berman JS, and Center DM: Lymphocyte chemoattractant factor (LCF) increases T4+ mononuclear cell migration and HLA-DR expression vice interaction with the T4 anigen. 6th international congress of immunology: 328, 1986.
7. Center DM, Berman JS, Theodore AC, and Cruikshank WW: Lymphokine Induction of Interleukin 2 Receptors On CD4+ Lymphocytes. Clin Res 35:453A, 1987.
8. Center DM, Cruikshank WW, Berman JS, Theodore AC, and Bernardo, J. T4 Antigen Dependant Lymphocyte and Monocyte Migration and Activation. Am Rev Resp Dis 135:A108, 1987.
9. Theodore AC, and Cruikshank WW. Binding of anti-CD3, anti-CD4 and anti-CD8 antibody to human T lymphocytes induces an association between the ligand-receptor complex and the cytoskeleton. Clin. Res. 38:232A, 1990.
10. Theodore AC, and Cruikshank WW. Effects of CD4 perturbation by HIV-1 gp120 on CD3 and CD4 cytoskeletal association and induced migration in human T lymphocytes. Clin. Res. 39:381A, 1991.
11. Theodore AC, O'Donnell,CM, and Cruikshank WW. The association of surfaced expressed CD4 with cytoskeletal proteins regulates CD3-induced human T lymphocyte migration. ASCB, 1991.
12. Theodore AC, O'Donnell CM. and Cruikshank WW. Modulation of CD4 by HIV-1 gp120 ablates CD3 and CD4-mediated T-Lymphocyte migration. ARRD, 145:A698, 1992.
13. Theodore AC, Kornfeld H, Center DM and Cruikshank WW. Suppression of the allogeneic response by the CD4 ligand lymphocyte chemoattractant factor. ARRD, 147:A230, 1993.
14. Theodore AC, Kornfeld H, Center DM and Cruikshank WW. Suppession of the immune response by a natural CD4-dependent interleukin. Resp. Crit. Care Med. May, 1995.
15. Theodore AC, Center DM, Cook J, Nicoll J, Kornfeld H, and Cruikshan WW. Costimulation of the TcR/CD3 complex in the presence of the CD4 ligand interleukin-16 induces functional anergy. Am. J. Resp. Crit. Care Med. 153:A790, 1996.
16. Theodore AC, Cook J, Parada N, Center DM and Cruikshank WW. Mechanism of
T lymphocyte unresponsiveness induced by interleukin-16 following T cellreceptor/CD3 stimulation. J. Invest. Med. 44:275A, 1996.
17. Theodore AC, Reilly J, Mentzer S, Wright E, Brazer W, and Cruikshank WW. IL-16 as an immunoregulatory cytokine in lung transplantation. Am. J. Resp. Crit. Care Med. 157:A759, 1998.
18. Theodore AC, Simms RW, Merkel PA, Clarke PD and JH Korn. Effects of intravenous cyclophosphamide and low dose prednisone on pulmonary function and HRCT in systemic sclerosis alveolitis. Am. J. Resp. Crit. Care Med. 159:53A, 1999.
19. Khanna D et. al. Baseline correlates of SF-36 in systemic sclerosis patients with active alveolitis-Preliminary results from 74 patients. Arthritis and Rheumitism. 2002.
20. Clements PJ, Tashkin D, Roth M, Golden J, Silver R, Sterz M, Furst DE, Elashoff R and the SLS investigators. Concordance of HRCT and BAL at entry into the Scleroderma Lung Study. Arthritis and Rheumitism. 2002
21. Theodore AC, Simms RW, Merkel PA and JH Korn. Treatment of Systemic Sclerosis Alveolitis with Intravenous Cyclophosphamide A.C. Am Rev Resp Crit Care Med. 167:A474, 2003
22. Strange C, R Silver, M Bolster, M Roth, J Goldin, R. Elashoff, PJ Clements, D Tashkin and the SLS investigators. Concordance of BAL and HRCT in the Scleroderma Lung Study. Am J Resp Crit Care Med. 167; A474, 2003.
23. Khanna D, Y Chon, DE Furst, PJ Clements, J Fitzgerald, J Goldin, M Roth, , R Elashoff, M Sterz and D Tashkin for Scleroderma Lung Study group. UCLA, Los Angeles. Baseline correlates of SF-36 in Systemic Sclerosis (SSc) patients with active alveolitis. Am J Resp Crit Care Med. 167; A472, 2003.
24. Clements PJ, Khanna D, Furst DE, Chon Y, Liu R, Tashkin D, Elashoff R for the Scleroderma Lung Study Group, The Degree of Dyspnea Correlates with Health Related Quality of Life( HRQOL), Functional Abilities, Patient Global Assessment, Forced Vital Capacity, (%FRC) and Diffusion Capacity (%DLCO) in Systemic Sclerosis (SSc) patients with active alveolitis. Arth. and Rheum. 48:S558, 2003.
25. Tashkin D, Clements P, Goldin J, Strange C, Silver R, Elashoff R and the SLS Research Group. The Scleroderma Lung Study (SLS): Baseline Features and Dyspnea-Lung Function Correlations. Am J Resp Crit Care Med. 167:A225, 2004.
26. Goldin J, Lynch D, Strollo R, Kim G, Tashkin D, Clements P, Elashoff R and the SLS Research Group. CT detection of alveolitis: Is there Inter-Reader agreement? Am J Resp Crit Care Med. 167:A106, 2004.
27. Silver R, Goldin J, Strange C, Lynch D, Strollo R, Tashkin DP , Clements P, Kim G, Elashoff R and the SLS Research Group. Alveolitis determination in Scleroderma Lung Disease: CT or Bronchoalveolar Lavage (BAL)? Am J Resp Crit Care Med. 167:A227, 2004.
28. Furst DE, Clements PJ, Tashkin DP, Elashoff R, Sterz M for the Scleroderma Lung Study. Among a group of patients with dyspnea and alveolitis entering the scleroderma lung study (SLS) a surprising proportion have limited Ssc. Arth. and Rheum, 50:S426, 2004.
29. Tashkin D, P Clements, M Roth, D Furst, C Strange, R Silver, J Goldin and R Elashoff for the Scleroderma Lung Study Research Group. Oral Cyclophosphamide versus Placebo for the Treatment of Scleroderma-Related Interstitial Lung Disease (SSc ILD): Main Findings from the Scleroderma Lung Study. AJRCCM. 17:, 2005.
30. Tashkin D, P Clements, M Roth, D Furst, C Strange, R Silver, J Goldin and R Elashoff for the Scleroderma Lung Study Research Group. One Year Course of Scleroderma-Related Interstitial Lung Disease (SSc ILD) in Patients with Limited vs. Diffuse SSc Treated with Oral Cyclophosphamide versus Placebo: Findings from the Scleroderma Lung Study. AJRCCM. 171: , 2005.
31. Keane MP, J Chung, W Liu, R Elashoff....and the Scleroderma Lung Study Group. Correlation of BAL chemokines with clinical parameters in scleroderma. AJRCCM. 173: A801, 2006.
32. Tashkin D, P Clements, M Roth, D Furst, C Strange, R Silver, J Goldin and R Elashoff from the Scleroderma Lung Study. Oral cyclphosphamide vs placebo for treatment of scleroderma interstitial lung disease: Main findings from the scleroderma lung study. AJRCCM. 173: A242, 2006.
33. Goldin J, D Lynch, D Strollo, C Strange, R Silver, P Clements, M Roth, D Furst, R Elashoff, DP Tashkin and the Scleroderma Research Group. High Resolution CT Findings in Scleroderma-Related Lung Diseases. AJRCCM. 173: A105, 2006.
34. Theodore AC, P.A. Merkel, E.Y. Kissin, and R.W. Simms. Systemic Sclerosis Alveolitis Treated with Intravenous Cyclophosphamide: Recurrence and Retreatment. AJRCCM. 175: A297. 2007.
35. Tashkin D, P Clements, M Roth, D Furst , R. Elashoff. In Patients with Scleroderma (SSc) Interstitial Lung Disease (ILD) Those with Limited vs Diffuse SSc Show Differences in Their Presentation and Response to Treatment with Oral Cyclophosphamide (Scleroderma Lung Study), AJRCCM. 175: A296. 2007.
36. Keane MP, R Elashoff, R Singh, J Chung, et al. Multiple BAL Cytokines as Correlates of Alveolitis in Scleroderma Lung Disease (Scleroderma Lung Study). AJRCCM. 175: A298. 2007.
37. Theodore AC and FF Little. Correlation of BAL Interleukin-16 with scleroderma Interstitial Lung disease activity and response to cyclophosphamide. Am J Respir Crit Care Med 181;2010:A1110.
38. Theodore AC, C-H Tseng and DP. Tashkin. Correlation of Cough with Disease Activity and Treatment with Cyclosphosphamide in Scleroderma Interstitial Lung Disease. Am J Respir Crit Care Med 181;2010:A2362.
39. Granada M and AC Theodore. Case Report: A Case Of Bronchocentric Granulomatosis Following Treatment For Non Hodgkin Lymphoma. Am J Respir Crit Care Med 181;2010:A4505.
40. Theodore AC, RW Simms, RA Lafyatis, EY Kissin, PA Merkel, WW Cruikshank and FF Little. A Preliminary investigation of the predictive value and response to therapy with cyclophosphamide of Interleukin-16 in Bronchoalveolar lavage in patients with Interstitial Lung disease in Systemic Sclerosis. Scleroderma Workshop, Boston, MA 2010.
Articles Theodore AC, Frank JA, Ende J, Snider GI, and Beer DJ: Errant Placement of Enteric Tubes - A Hazard in Obtunded Patients. Chest 86(6):931, 1984.
Theodore AC, and Snider GL: The Solitary Pulmonary Nodule. J. Resp Dis 5(9):15, 1984.
Berman JS, Cruikshank WW, Center DM, Theodore AC, Beer DJ: 1985. Chemoattractant lymphokines specific for the helper-inducer T-lymphocyte subset. Cell Immunol 95:105,
Theodore AC, Center DM, Cruikshank WW, and Beer DJ: A human T-T cell hybridoma derived lymphocyte chemoattractant factor. Cell Immunol 98:411-421, 1986.
Cruikshank WW, Berman JS, Theodore AC, Bernardo J, and Center DM: Lymphokine interaction with the T4 Antigen Induces T Lymphocyte and Monocyte Activation. J Immunol 138:3817, 1987.
Leslie CA, Theodore AC, Cathcart EA. Fish oil diets modify chemoattractants from mouse macrophages. J Am Rheum Assoc, 1988.
Berman JS, Cruikshank WW, Kornfeld H, Bernardo J, Theodore AC, and Center DM. Lymphocyte Motility and Lymphocyte Chemoattractant Factors. Immunol Invest 17:625, 1988.
Berman JS, Beer DJ, Theodore AC, Kornfeld H, Bernardo J, and Center DM. State of the Art: Lymphocyte recruitment to the lung. ARRD, 142:238-57, 1990.
Center DM, Berman JS, Kornfeld H, Theodore AC, and Cruikshank WW. Mechanisms of lymphocye accumulation in pulmonary disease. Chest (Sup) 103:88-91S. 1993.
Cruikshank WW, Center DM, Nisar N, Natke B, Wu M, Theodore AC, and Kornfeld H. Molecular cloning of a CD4-binding lymphokine. PNAS. 91: 5109-5113, 1994.
Theodore AC, O'Donnell, Wallace RP, Kornfeld H, and Cruikshank WW. CD4-modulation of non-infected human T lymphocytes by HIV-1 envelope gp120: Contribution to the immunosuppression seen in HIV-1 infection by induction of CD4 and CD3 unresponsiveness. JAIDS. 7: 7899-907, 1994.
Center DM, Kornfeld H, Wu M, Falvo M. Theodore AC, Bernardo J, Berman JS, and Cruikshank WW. Cytokine Binding to CD4+ Inflammatory Cells: Implications for Asthma. Amer. J. Resp. Crit. Care Med. 150: S59-S62, 1994.
Center DM, Berman JS, Kornfeld H, Theodore AC, and Cruikshank WW. The Lymphocyte Chemoattractant Factor. Lab. Clin. Med. 125:167-72, 1995.
Theodore, AC, Center DM, Nicoll J, Fine G, Kornfeld H, and WW Cruikshank. CD4 ligand Interleukin-16 inhibits the Mixed Lymphocyte Reaction. J. Immunol. 157:1958-64, 1996.
Cruikshank WW, Lim K, Theodore AC, Cook J, Fine G, Weller PF and Center DM. IL-16 Inhibition of CD3 dependent Lymphocyte Activation and Proliferation. J. Immunol. 157:5240-9, 1996.
Wilson KC, Reardon C, Theodore AC, and HW. Farber, M.D. Propylene glycol toxicity: A potentially life-threatening iatrogenic illness and a common cause of metabolic abnormality in MICU patients receiving intravenous benzodiazepines. Chest 128:1674-1681, 2005.
Khanna D , PJ Clements, DE Furst, Y Chon, R Elashoff, MD Roth, MG Sterz, J Chung, JD FitzGerald, JR Seibold, J Varga, AC Theodore, F Wigley, RM Silver, V Steen, M Mayes, K Connolly, BJ Fessler, NRothfield, K Mubarak, J Molitor, and DP Tashkin, for the Scleroderma Lung Study Group. Correlation of the Degree of Dyspnea with Health-Related Quality of Life, Functional Abilities and Diffusing Capacity for Carbon Monoxide in Patients with Systemic Sclerosis and Active Alveolitis: Results from the Scleroderma Lung Study. Arthritis & Rheumatism, Vol. 52, No. 2, February 2005: p. 592-600.
Highland KB and RM Silver. Clinical Aspects of Lung Involvement: Lessons from Idiopathic Pulmonary Fibrosis and the Scleroderma Lung Study. Current Rheumatology Reports April 1 2005, 7: 135-141.
Tashkin D., et al. The Scleroderma Lung Study: Oral Cyclophosphamide versus Placebo for the Treatment of Scleroderma-Related Interstitial Lung Disease. NEJM 354(25); 2655-2666, 2006.
Goldin JG, Johnson T, McNitt-Gray MF, Brown MS, Emerick AM, Kaplan AM and the Scleroderma Lung Study Group. Noninvasive assessment of alveolitis and fibrosis in scleroderma lung disease. Radiology 2000; 217(P) (Suppl):423.
PJ Clements, JG Goldin, EC Kleerup, DE Furst, RM Eloshoff, DP Tashkin, MD Roth and the Scleroderma Lung Study Group. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis & Rheumatism, Vol. 50, No. 6, June 2004: p. 1909-1917.
JC Cole, D Khanna, PJ Clements, JR Seibold, DP Tashkin, HE Paulus, MR Irwin, SJ Motivala, DE Furst and on behalf of the Slceroderma Lung Study (SLS) and Relaxin Study. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Quality of Life Research 2006, 15(7): 1383-1394. (July 7 2006. online).
Khanna D, Yan X, Tashkin D., et al. Impact of oral cyclophosphmide on Health-related Quality of Life in Patients with active scleroderma lung disease. Results from the Scleroderma Lung Study. Arthritis & Rheumatism 2007, 56:1676-1684.
Tashkin DP, Elashoff R, ClementsPJ, RothMD, FurstDE,. SilverRM, GoldinJ, ArriolaE, StrangeC,. BolsterMB, SeiboldJR, RileyDR, Hsu VM, VargaJ, SchraufnagelD, TheodoreA, SimmsR, WiseR, WigleyF, WhiteB, SteenV, ReadC, MayesM, ParsleyE, MubarakK,ConnollyM, GoldenJ, OlmanM,FesslerF, RothfieldN, MeterskyM, KhannaD, LiN, and Li G.for the Scleroderma Lung Study (SLS) Research Group* Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. AJRCCM. 176:1026-1034, 2007.
26. Elashoff RM, Li G and Li N., for the Scleroderma Lung Study. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Stat med 2007: 26 (14):2813-35.
27. Clements PJ, Roth MD Furst DE et al. Scleroderma Lung Study (SLS). Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007: 66(12):1641-7.
28. Strange C, BolsterMB, RothMD ,SilverRM, TheodoreA, et. al. and the Scleroderma Lung Study Research Group. Bronchoalveolar Lavage and the Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease. American Journal of Respiratory & Critical Care Medicine. 177(1):91-8, 2008.
29. Marshall J, Finn CA and AC Theodore. Impact of a clinical pharmacist enforced ICU sedation protocol on duration of mechanical ventilation and hospital stay. Critical Care Medicine, 36(2):427-33, 2008.
30. Kim HJ, Li, G, Gjertson D et al. (SLS). Classification of parenchymal abnormality in scleroderma using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008; 15(8):1004-16.
Elashoff RM, Li G, Li N. (SLS). A joint model for longitudinal measurements and survival data in the presence of multiple failure types. Biometrics 2008: 64(3): 762-71.
31. Khanna D, Furst DE Clements PJ et al. (SLS). Oral cyclophosphamide for active scleroderma lung disease: A decision analysis. Med Decis Making 2008; 28(6); 926-37.
32. Goldin, JG, DA Lynch, DC Strollo, et al; for the Scleroderma Lung Study Research Group. High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease. Chest. 134(2):358-367, 2008.
33. Kim HJ, Li G, Gjertson D et al. (SLS). Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008; 15(8): 1004-16.
34. Li N, Elashoff RM, Li G. (SLS) Robust joint remodeling of longitudinal measurements and competing risks failure time data. Biom J 2009; 51(1); 19-30.
35. Au K, Khanna D, Clements PJ et al. (SLS) Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Current Rheum Reports. 2009; 11(20: 111-9.
36. Khanna D, Tseng C-H, Li N et al. For Scleroderma Lung Study Investigators. Minimally important differences in the Mahler’s Transitional Dyspnea Index in a large randomized controlled trial: Results from the Scleroderma Lung Study. Rheumatology; 2009: 48(12): 1537-40.
37. Hant FN, Ludwicka-Bradley A, Wang HJ et al. Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with Scleroderma. J Rheumatol 2009; 36(4): 773-80.
38. Goldin, Jonathan G; Elashoff, Robert, Kim, H.J. et al. Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo: Findings From the Scleroderma Lung Study Chest. 136:1333-1340. 2009.
39. Hsu VM, Khanna D, Smith E et al. Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the Scleroderma Lung Study (SLS). Clin Trials 2010; 7(1):85-89.
40. Theodore AC, Tseng C-H and D Tashkin. Correlation of Cough with Disease Activity and Treatment with Cyclosphosphamide in Scleroderma Interstitial Lung Disease. Findings from the Scleroderma Lung Study Submitted.
1. Theodore AC, Beer DJ: “Pharmacotherapy of Chronic Obstructive Pulmonary Disease.” In: Chest Clinics of North America; Pulmonary Rehabilitation Ed. by B. Make. 7:657, 1986.
2. Beer DJ, Cruikshank WW, Berman JS, Theodore AC, Center DM. “Histamine-Induced Human Lymphocyte Chemoattractant Lymphokines: Mechanisms for the Amplification of Cell Mediated Immune Responses.” In: The Effects of Histamine and Histamine-type 2 Antagonists in Inflamation and Immunodeficiency. R. Rocklin, ed. Marcel Dekker, NY, 1988.
3. Reardon C, and Theodore, AC. “Lung Cancer.” In: A Practical Approach to Pulmonary Medicine, ed. by R. Goldstein and J. Karlinsky. Lipincott-Raven, Philadelphia, 1997.
4. Cruikshank WW, Parada N., Ryan T., Vigliante G, Theodore AC and DM Center. “Measurement of Human Interleukin 16.” In: Current Protocols in Immunology. 1997.
Wilson, KC, Theodore, AC. Smoke and carbon monoxide inhalation. In, The Intensive Care Unit Manual, 2nd Edition (Eds, Lanken, PN, Hanson, CW, and Manaker, S). Elsevier, St. Louis, MO. 2010. In press.
Letters to the Editor
1. Theodore, AC and K. Wilson. An Unseen Danger: Frequency of posterior wall vessel penetration by needles during atttempts to place internal jugular vein catheters using ultrasound guidance. Crit Care Med. 38:345, 2010.